198 related articles for article (PubMed ID: 20880107)
1. The class-I HDAC inhibitor MGCD0103 induces apoptosis in Hodgkin lymphoma cell lines and synergizes with proteasome inhibitors by an HDAC6-independent mechanism.
Buglio D; Mamidipudi V; Khaskhely NM; Brady H; Heise C; Besterman J; Martell RE; MacBeth K; Younes A
Br J Haematol; 2010 Nov; 151(4):387-96. PubMed ID: 20880107
[TBL] [Abstract][Full Text] [Related]
2. PCI-24781 induces caspase and reactive oxygen species-dependent apoptosis through NF-kappaB mechanisms and is synergistic with bortezomib in lymphoma cells.
Bhalla S; Balasubramanian S; David K; Sirisawad M; Buggy J; Mauro L; Prachand S; Miller R; Gordon LI; Evens AM
Clin Cancer Res; 2009 May; 15(10):3354-65. PubMed ID: 19417023
[TBL] [Abstract][Full Text] [Related]
3. The histone deacetylase inhibitor entinostat (SNDX-275) induces apoptosis in Hodgkin lymphoma cells and synergizes with Bcl-2 family inhibitors.
Jóna A; Khaskhely N; Buglio D; Shafer JA; Derenzini E; Bollard CM; Medeiros LJ; Illés A; Ji Y; Younes A
Exp Hematol; 2011 Oct; 39(10):1007-1017.e1. PubMed ID: 21767511
[TBL] [Abstract][Full Text] [Related]
4. Combination of proteasome and class I HDAC inhibitors induces apoptosis of NPC cells through an HDAC6-independent ER stress-induced mechanism.
Hui KF; Chiang AK
Int J Cancer; 2014 Dec; 135(12):2950-61. PubMed ID: 24771510
[TBL] [Abstract][Full Text] [Related]
5. MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo.
Fournel M; Bonfils C; Hou Y; Yan PT; Trachy-Bourget MC; Kalita A; Liu J; Lu AH; Zhou NZ; Robert MF; Gillespie J; Wang JJ; Ste-Croix H; Rahil J; Lefebvre S; Moradei O; Delorme D; Macleod AR; Besterman JM; Li Z
Mol Cancer Ther; 2008 Apr; 7(4):759-68. PubMed ID: 18413790
[TBL] [Abstract][Full Text] [Related]
6. The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571.
Yu C; Rahmani M; Conrad D; Subler M; Dent P; Grant S
Blood; 2003 Nov; 102(10):3765-74. PubMed ID: 12893773
[TBL] [Abstract][Full Text] [Related]
7. Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma.
Santo L; Hideshima T; Kung AL; Tseng JC; Tamang D; Yang M; Jarpe M; van Duzer JH; Mazitschek R; Ogier WC; Cirstea D; Rodig S; Eda H; Scullen T; Canavese M; Bradner J; Anderson KC; Jones SS; Raje N
Blood; 2012 Mar; 119(11):2579-89. PubMed ID: 22262760
[TBL] [Abstract][Full Text] [Related]
8. The histone deacetylase inhibitor MGCD0103 induces apoptosis in B-cell chronic lymphocytic leukemia cells through a mitochondria-mediated caspase activation cascade.
El-Khoury V; Moussay E; Janji B; Palissot V; Aouali N; Brons NH; Van Moer K; Pierson S; Van Dyck E; Berchem G
Mol Cancer Ther; 2010 May; 9(5):1349-60. PubMed ID: 20406947
[TBL] [Abstract][Full Text] [Related]
9. Synergistic interaction between the novel histone deacetylase inhibitor ST2782 and the proteasome inhibitor bortezomib in platinum-sensitive and resistant ovarian carcinoma cells.
Gatti L; Benedetti V; De Cesare M; Corna E; Cincinelli R; Zaffaroni N; Zunino F; Perego P
J Inorg Biochem; 2012 Aug; 113():94-101. PubMed ID: 22717676
[TBL] [Abstract][Full Text] [Related]
10. Induction of cell cycle arrest and apoptosis by the proteasome inhibitor PS-341 in Hodgkin disease cell lines is independent of inhibitor of nuclear factor-kappaB mutations or activation of the CD30, CD40, and RANK receptors.
Zheng B; Georgakis GV; Li Y; Bharti A; McConkey D; Aggarwal BB; Younes A
Clin Cancer Res; 2004 May; 10(9):3207-15. PubMed ID: 15131062
[TBL] [Abstract][Full Text] [Related]
11. Dual Targeting of Protein Degradation Pathways with the Selective HDAC6 Inhibitor ACY-1215 and Bortezomib Is Synergistic in Lymphoma.
Amengual JE; Johannet P; Lombardo M; Zullo K; Hoehn D; Bhagat G; Scotto L; Jirau-Serrano X; Radeski D; Heinen J; Jiang H; Cremers S; Zhang Y; Jones S; O'Connor OA
Clin Cancer Res; 2015 Oct; 21(20):4663-75. PubMed ID: 26116270
[TBL] [Abstract][Full Text] [Related]
12. Limited efficacy of specific HDAC6 inhibition in urothelial cancer cells.
Rosik L; Niegisch G; Fischer U; Jung M; Schulz WA; Hoffmann MJ
Cancer Biol Ther; 2014 Jun; 15(6):742-57. PubMed ID: 24618845
[TBL] [Abstract][Full Text] [Related]
13. Expression of histone deacetylases in lymphoma: implication for the development of selective inhibitors.
Gloghini A; Buglio D; Khaskhely NM; Georgakis G; Orlowski RZ; Neelapu SS; Carbone A; Younes A
Br J Haematol; 2009 Nov; 147(4):515-25. PubMed ID: 19775297
[TBL] [Abstract][Full Text] [Related]
14. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
Pei XY; Dai Y; Grant S
Clin Cancer Res; 2004 Jun; 10(11):3839-52. PubMed ID: 15173093
[TBL] [Abstract][Full Text] [Related]
15. HDAC inhibitor L-carnitine and proteasome inhibitor bortezomib synergistically exert anti-tumor activity in vitro and in vivo.
Huang H; Liu N; Yang C; Liao S; Guo H; Zhao K; Li X; Liu S; Guan L; Liu C; Xu L; Zhang C; Song W; Li B; Tang P; Dou QP; Liu J
PLoS One; 2012; 7(12):e52576. PubMed ID: 23285100
[TBL] [Abstract][Full Text] [Related]
16. Combination of SAHA and bortezomib up-regulates CDKN2A and CDKN1A and induces apoptosis of Epstein-Barr virus-positive Wp-restricted Burkitt lymphoma and lymphoblastoid cell lines.
Hui KF; Leung YY; Yeung PL; Middeldorp JM; Chiang AK
Br J Haematol; 2014 Dec; 167(5):639-50. PubMed ID: 25155625
[TBL] [Abstract][Full Text] [Related]
17. Histone deacetylase inhibitor depsipeptide (FK228) induces apoptosis in leukemic cells by facilitating mitochondrial translocation of Bax, which is enhanced by the proteasome inhibitor bortezomib.
Sutheesophon K; Kobayashi Y; Takatoku MA; Ozawa K; Kano Y; Ishii H; Furukawa Y
Acta Haematol; 2006; 115(1-2):78-90. PubMed ID: 16424655
[TBL] [Abstract][Full Text] [Related]
18. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma.
Heider U; von Metzler I; Kaiser M; Rosche M; Sterz J; Rötzer S; Rademacher J; Jakob C; Fleissner C; Kuckelkorn U; Kloetzel PM; Sezer O
Eur J Haematol; 2008 Feb; 80(2):133-42. PubMed ID: 18005386
[TBL] [Abstract][Full Text] [Related]
19. Nuclear factor-kappaB p65 small interfering RNA or proteasome inhibitor bortezomib sensitizes head and neck squamous cell carcinomas to classic histone deacetylase inhibitors and novel histone deacetylase inhibitor PXD101.
Duan J; Friedman J; Nottingham L; Chen Z; Ara G; Van Waes C
Mol Cancer Ther; 2007 Jan; 6(1):37-50. PubMed ID: 17237265
[TBL] [Abstract][Full Text] [Related]
20. Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells.
Nawrocki ST; Carew JS; Pino MS; Highshaw RA; Andtbacka RH; Dunner K; Pal A; Bornmann WG; Chiao PJ; Huang P; Xiong H; Abbruzzese JL; McConkey DJ
Cancer Res; 2006 Apr; 66(7):3773-81. PubMed ID: 16585204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]